Immune booster: NK cells join standard care for advanced cancers
Disease control
Not yet recruiting
This early-phase study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced solid tumors, including non-small cell lung cancer and colorectal cancer. About 20 adults aged 18-75 will receive NK cell infusions alongsi…
Phase: PHASE1, PHASE2 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC